参松养心胶囊治疗老年肺心病合并室性期前收缩的临床研究  

Clinical Study of Shensongyangxin capsule in Treating Chronic Pulmonary Heart Disease Complicated by Ventricular Contractions

作　　者：张金龙[1] 谭亚萍[1] 

机构地区：[1]四川省绵阳市中医医院,621000

出　　处：《中国老年保健医学》2017年第2期33-35,共3页Chinese Journal of Geriatric Care

摘　　要：目的探讨参松养心胶囊治疗老年慢性肺心病合并频发室性期前收缩的临床疗效和安全性。方法将于2013年6月至2015年12月我院收治的84例老年慢性肺心病合并频发室性期前收缩患者随机分为治疗组和对照组,其中治疗组在对照组的基础上加用参松养心胶囊治疗,并与采用常规综合治疗的对照组进行临床疗效和不良反应的对比研究。结果治疗组临床疗效和心电图改变均明显优于对照组(P<0.05)。治疗组患者治疗后对血液流变学改善情况明显优于对照组(P<0.05)。治疗后,治疗组室性期前收缩次数明显低于对照组(P<0.05)。结论参松养心胶囊治疗慢性肺心病合并频发室性期前收缩的疗效确切,安全性较好。Objectives To investigate the clinical effect of Shensongyangxin capsule in treating chronic pulmonary heart disease complicated by ventricular contractions. Methods This study in 2013-06 - 2015-12November in 84 accordance with the random number table method treated the chronic pulmonary heart disease complicated with recurrent patients were randomly divided into study group and control group of premature ventricular contraction,the research group was treated with Shensongyangxin capsule, and carries out a comparative research on the clinical efficacy and adverse reactions and the control group with routine comprehensive therapy the. Results The study group was significantly better than the control group in the clinical curative effect and electrocard io- graph （ECG） efficacy （P 〈 O. 05 ）. Patients in the study group after treatment on hemorheology significantly higher than those in control group（P 〈 0. 05 ）. After treatment, the study group ventricular extrasystoles times lower than that of control group （ P 〈 0. 05）. Conclusion Shensongyangxin capsule in the treatment of chronic pulmonary heart disease complicated by ventricular con- tractions had curative effect ,less adverse reaction, and easy to accept.

关 键 词：参松养心胶囊 慢性肺心病 室性期前收缩 

分 类 号：R259[医药卫生—中西医结合]